Valuation: Ligand Pharmaceuticals Incorporated

Market Cap 5.59B 4.78B 4.48B 4.09B 7.73B 533B 7.8B 52.79B 20.57B 268B 20.97B 20.51B 889B P/E 2026 *
53.8x
P/E 2027 * 33x
Enterprise Value 5.59B 4.78B 4.48B 4.09B 7.73B 533B 7.8B 52.79B 20.57B 268B 20.97B 20.51B 889B EV / Sales 2026 *
19.3x
EV / Sales 2027 * 14.7x
Free-Float
97.62%
Yield 2026 *
-
Yield 2027 * -
1 day+0.55%
1 week-3.44%
Current month-2.02%
1 month-6.26%
3 months+22.84%
6 months+49.06%
Current year+49.00%
1 week 278.28
Extreme 278.28
294.6
1 month 278.28
Extreme 278.28
317.49
Current year 175.89
Extreme 175.89
326.63
1 year 158.13
Extreme 158.13
326.63
3 years 49.24
Extreme 49.24
326.63
5 years 49.24
Extreme 49.24
326.63
10 years 49.24
Extreme 49.24
326.63
Manager TitleAgeSince
Chief Executive Officer 65 05/12/2022
Director of Finance/CFO 47 21/05/2015
Director of Finance/CFO 56 01/11/2022
Director TitleAgeSince
Chairman 76 01/03/2003
Director/Board Member 57 27/09/2006
Director/Board Member 65 01/03/2007
Date Insider Type Main position Quantity % Market Cap.
12/08/26 Fiscal year

Chief Financial Officer

94,923 0.4736%
12/08/26 Fiscal year

Director

19,414 0.0969%
03/08/26 Fiscal year

General Counsel

15,000 0.0748%
Change 5-day change 1-year change 3-year change Capi.($)
+0.55%-3.44%+77.09%+326.33% 5.59B
-1.06%+4.27%+73.34%+125.12% 1,111B
+0.53%+4.10%+52.35%+65.45% 658B
+0.48%+6.18%+26.21%+81.27% 467B
+0.92%+4.97%+42.94%+43.69% 369B
+1.25%+4.00%+25.87%+42.82% 301B
+3.02%+7.92%+4.24%+16.06% 256B
-0.36%+5.45%+50.57%+72.33% 240B
+2.86%+5.27%-15.42%-52.34% 207B
+1.38%+7.09%+29.62%+94.90% 182B
Average +1.08%+3.65%+36.68%+81.56% 379.66B
Weighted average by Cap. +1.03%+4.67%+44.17%+73.45%

Financials

2026 *2027 *
Net sales 290M 248M 232M 212M 401M 27.65B 405M 2.74B 1.07B 13.93B 1.09B 1.06B 46.14B 381M 326M 305M 279M 527M 36.3B 531M 3.6B 1.4B 18.29B 1.43B 1.4B 60.58B
Net income 112M 95.8M 89.62M 81.95M 155M 10.67B 156M 1.06B 412M 5.38B 420M 411M 17.81B 187M 160M 150M 137M 259M 17.83B 261M 1.77B 688M 8.98B 702M 686M 29.75B
Net Debt - -
Logo Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It operates as a royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. It owns and manages portfolios of biopharmaceutical royalties, with economic interests in more than 200 development and commercial-stage assets. It funds high-value programs in exchange for long-term economic interests. It also licenses its proprietary technologies, Captisol and NITRICIL, to support drug development and formulation across its global partner network. Its commercial products include Roche's VABYSMO (faricimab-svoa), Servier's OJEMDA (tovorafenib), and Zevra Therapeutics' MIPLYFFA (arimoclomol). Additionally, it includes 14 late-stage development programs, featuring Takeda’s mezagitamab and certain assets from Takeda’s externalized asset portfolio, such as osavampator, volixibat, and OHB-607, along with more than 100 assets in various stages of development.
Employees
47
Date Price Change Volume
25/08/26 $281.72 +0.55% 197,400
24/08/26 $280.18 -2.13% 158,235
21/08/26 $286.29 -0.38% 152,536
20/08/26 $287.39 -1.14% 138,945
19/08/26 $290.71 +1.08% 231,199
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
281.72USD
Average target price
342.82USD
Spread / Average Target
+21.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LGND Stock